Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas

This publication has 66 references indexed in Scilit:

• ¹⁸FDG positron emission tomography versus ⁶⁷Ga scintigraphy as prognostic test during chemotherapy for non‐Hodgkin's lymphoma
  British Journal of Haematology, 2003
• Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation
  Blood, 2003
• Utility of FDG-PET scanning in lymphoma by WHO classification
  Blood, 2003
• Pre-transplant positron emission tomography (PET) using fluorine-18-fluoro-deoxyglucose (FDG) predicts outcome in patients treated with high-dose chemotherapy and autologous stem cell transplantation for non-Hodgkin's lymphoma
  Bone Marrow Transplantation, 2002
• FDG PET in the management of lymphoma: a clinical perspective
  European Journal of Nuclear Medicine and Molecular Imaging, 2002
• Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation
  Leukemia, 2002
• Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
  Blood, 2001
• Positron Emission Tomography (PET) for Staging Low-Grade Non-Hodgkin's Lymphomas (NHL)
  Cancer Biotherapy & Radiopharmaceuticals, 2001
• Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
  European Journal Of Cancer, 2000
• Positron Emission Tomography with 18-Fluorodeoxyglucose in the Staging and Follow-up of Lymphoma in the Chest
  Acta Oncologica, 1999